The company also announced the appointment of Han Lee, Ph.D., as co-chief executive officer (CEO), and the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) ...
The company will use the funds to advance its drug design platform and lead program in EGFR-expressing solid tumors and expand globally.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback